Subject
Behavioral Neuroscience,Neurology (clinical),Neurology
Reference16 articles.
1. UCB I. FINTEPLA® (fenfluramine) oral solution [prescribing information]. Smyrna, GA March 2023.
2. Zogenix ROI Limited. Fintepla 2.2 mg/mL oral solution [summary of product characteristics]. Dublin, IE: Zogenix ROI Limited; April 20 2023.
3. UCB Japan Co. LTD. Fintepla Oral Solution 2.2 mg/mL [prescribing information]. Tokyo, Japan September 26 2022.
4. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial;Nabbout;JAMA Neurol,2020
5. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial;Lagae;Lancet,2019